Prosecution Insights
Last updated: April 19, 2026
Application No. 18/564,869

DENTAL COMPOSITION AND DENTINE CULTURING METHOD

Non-Final OA §102§103
Filed
Nov 28, 2023
Examiner
KELLY, ROBERT M
Art Unit
1638
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Air Water Inc.
OA Round
1 (Non-Final)
74%
Grant Probability
Favorable
1-2
OA Rounds
2y 11m
To Grant
99%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allow Rate
671 granted / 906 resolved
+14.1% vs TC avg
Strong +24% interview lift
Without
With
+24.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
44 currently pending
Career history
950
Total Applications
across all art units

Statute-Specific Performance

§101
4.5%
-35.5% vs TC avg
§103
15.3%
-24.7% vs TC avg
§102
17.3%
-22.7% vs TC avg
§112
35.1%
-4.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 906 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-8 are pending as originally filed, and are considered herein. Formalities The specification of 11/28/23, is accepted. The drawings of 11/28/23, are accepted. The IDS filings of 11/28/23 have been considered and are signed-off upon, herein. Applicant’s priority is through 371 to PCT/JP2022/014543, filed 3/25/22, and back to Japanese Application No. 2021-090610, filed 5/28/21. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 1-3, 5, and 8 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by U.S. Patent Publication No. 2019/0282675 A1 to Misako, et al., published more than a year before Applicant’s earliest filing date. Claim(s) 1-3, 5, and 8 is/are rejected under 35 U.S.C. 102(a)(2) as being anticipated by U.S. Patent Publication No. 2019/0282675 A1 to Misako, et al. The applied reference has a common inventor with the instant application. Based upon the earlier effectively filed date of the reference, it constitutes prior art under 35 U.S.C. 102(a)(2). This rejection under 35 U.S.C. 102(a)(2) might be overcome by: (1) a showing under 37 CFR 1.130(a) that the subject matter disclosed in the reference was obtained directly or indirectly from the inventor or a joint inventor of this application and is thus not prior art in accordance with 35 U.S.C. 102(b)(2)(A); (2) a showing under 37 CFR 1.130(b) of a prior public disclosure under 35 U.S.C. 102(b)(2)(B) if the same invention is not being claimed; or (3) a statement pursuant to 35 U.S.C. 102(b)(2)(C) establishing that, not later than the effective filing date of the claimed invention, the subject matter disclosed in the reference and the claimed invention were either owned by the same person or subject to an obligation of assignment to the same person or subject to a joint research agreement. Claim 1: Misako teaches crushing tooth into grains, to obtain fine dentin particles having about 500-1000 micrometer size, which are separated by a sieve. This is done in the context of inducing dentin by dental pulp stem cells (Example 2). The context of this is to then treat dogs’ with root canals (Example 3). The same is taught to be done for humans (paragraph 61), which is taught with human dental pulp (e.g. Example 8). These examples are taught in the context of treating humans (e.g., paragraph 4 and 26). Claim 2: as above, the particles are 500-1000 micrometers in size. Claim 3: Example 2 teaches the demineralization with EDTA. Claim 4: Claim 5: Example 2 teaches 1 mM EDTA for demineralization. Claim 6: Claim 7: Claim 8: The composition is made and cultured (Example 2). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1-5 and 8 is/are rejected under 35 U.S.C. 103 as being unpatentable over U.S. Patent Publication No. 2019/0282675 A1 to Misako, et al. and U.S. Patent Application Publication No. 2009/017184 A1. As shown above, the base claims are anticipated by the base art. However, the aspect of utilizing a 0.4-1.0 Normal strong acid as a demineralization solution, is not taught by Misako’s 2019/0282675 Publication. On the other hand, it has long been known to do so in the art, at the time of invention. For example, 10-20% HCl or HNO3 is known to be utilized for decalcifying teeth in Misako’s 2009/0176184 Publication (e.g., paragraph 24). Thus, the invention is obvious. The Artisan would do so as another method of decalcifying the ground teeth. The Artisan would expect success, as the components are utilized for art-recognized purposes. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1-3 and 5-8 is/are rejected under 35 U.S.C. 103 as being unpatentable over U.S. Patent Publication No. 2019/0282675 A1 to Misako, et al. and U.S. Patent Publication No. 2018/0296445 A1 to Amao, et al., JP Publication No. 11-228328 to Abiru, et al. (machine translation), and JP Pub. No. 2018-131456 to Takahashi. As shown above, the base claims are rejected over the base art alone, but the aspects of immersion in alcohol comprising silver ions as an antimicrobial agent and drying. On the other hand, in making such preparations, silver ions are well known in the art, as antimicrobial for such purposes (e.g., Amao, paragraphs 90-94; Abiru, paragraph 10 and Claim 2; and Takahashi, paragraphs 27-29 and Claim 1). Thus, at the time of invention, the invention was obvious. The Artisan would do so to make material for treatment of root canals in dogs and humans. The Artisan would expect success, as it is claimed. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ROBERT M KELLY whose telephone number is (571)272-0729. The examiner can normally be reached M-F: 8a-5p. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Tracy Vivlemore can be reached at 571-272-2914. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. ROBERT M. KELLY Examiner Art Unit 1638 /ROBERT M KELLY/Primary Examiner, Art Unit 1638
Read full office action

Prosecution Timeline

Nov 28, 2023
Application Filed
Feb 13, 2026
Non-Final Rejection — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599679
Circular RNA Compositions
2y 5m to grant Granted Apr 14, 2026
Patent 12594341
MULTIFUNCTIONAL IMMUNOTHERAPEUTIC MONOCLONAL ANTIBODY COMPLEXES AND CONJUGATES
2y 5m to grant Granted Apr 07, 2026
Patent 12590189
PROCESSES AND SYSTEMS FOR PREPARING CELLULAR OR VIRAL MEMBRANES AND NANOPARTICLES
2y 5m to grant Granted Mar 31, 2026
Patent 12582698
CELLULAR REPROGRAMMING TO REVERSE AGING AND PROMOTE ORGAN AND TISSUE REGENERATION
2y 5m to grant Granted Mar 24, 2026
Patent 12577293
METHOD FOR THE EXPRESSION OF POLYPEPTIDES USING MODIFIED NUCLEIC ACIDS
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
74%
Grant Probability
99%
With Interview (+24.5%)
2y 11m
Median Time to Grant
Low
PTA Risk
Based on 906 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month